USFDA inspection ends with ‘Zero’ observations: Alkem

At the end of the inspection, no form 483 was issued, the company added.

173
USFDA
Picture: Pixabay

Last Updated on August 1, 2021 by The Health Master

Drug firm Alkem Laboratories yesterday said the US health regulator has conducted an inspection of its Taloja facility in Maharashtra, and it ended with ‘zero’ observations.

The US Food and Drug Administration (USFDA) had conducted a remote and virtual bio-analytical inspection of the company’s Bioequivalence Center located at Taloja, Maharashtra from 26th to 28th July, 2021, Alkem Laboratories said in a regulatory filing.

At the end of the inspection, no form 483 was issued, the company added.

A form 483 is issued by the USFDA to notify a company’s management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection.

Granules Pharma clears USFDA audit

Zydus Cadila gets USFDA nod for Ibrutinib tablets

Lupin gets USFDA nod for generic Antifungal drug

Unichem gets tentative USFDA nod for drug to treat Diabetes

Alembic gets USFDA final nod for Erlotinib Tablets

Alembic gets USFDA nod for drug for the treatment of Depression

India and Pharmacy Education: Chapter: 2

88% price reduction of 5 Medical Devices reported: NPPA

FDA approves 7 more units to manufacture Remdesivir

Pharmexcil seeks list of products from Pharma Exporters

NPPA fixes ceiling prices of 355 Medicines and 882 Formulations

CDSCO classifies 208 Medical Devices in various categories

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner